PharmAbcine Inc
208340
Company Profile
Business description
PharmAbcine Inc is a clinical stage biotech company that develops fully human therapeutic monoclonal antibody (mAb) using innovative discovery technology and excellent human resources for the treatment of human diseases, such as cancer and inflammatory diseases.
Contact
70, 2, 2nd Floor, KT Daedeok 2 Research Center
Jeonmin-dong
Yuseong-dong
Daejeon Metropolitan City1689
KORT: +82 428632017
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
39
Stocks News & Analysis
stocks
Unconventional wisdom: Are dividends the answers?
As investors toil in complexity the obvious solution may be the right one.
stocks
Netflix: A business that’s nearly flawless
Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks
Trump’s US dollar assault is fuelling CBA’s rise
A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,934.30 | 45.10 | -0.50% |
| CAC 40 | 7,838.21 | 19.93 | 0.25% |
| DAX 40 | 24,231.39 | 64.54 | -0.27% |
| Dow JONES (US) | 44,789.68 | 95.77 | 0.21% |
| FTSE 100 | 9,121.43 | 16.94 | -0.19% |
| HKSE | 25,388.35 | 278.83 | -1.09% |
| NASDAQ | 21,098.04 | 40.08 | 0.19% |
| Nikkei 225 | 41,456.23 | 370.11 | -0.88% |
| NZX 50 Index | 12,853.46 | 48.33 | 0.38% |
| S&P 500 | 6,378.38 | 15.03 | 0.24% |
| S&P/ASX 200 | 8,666.90 | 42.50 | -0.49% |
| SSE Composite Index | 3,593.66 | 12.07 | -0.33% |